EGFR-TKIs 一线治疗晚期非小细胞肺癌的有效性和安全性比较: 网状Meta 分析
张慧芳， 马金沙， 李璐， 高倩， 王彤 - 中华疾病控制杂志, 2020 - zhjbkz.ahmu.edu.cn
… 小细胞肺癌(non-small cell lung cancer, NSCLC)的有效性和安全性. … compare the efficacy
and safety of gefitinib, erlotinib, and afatinib in the first-line treatment of advanced non-small cell …
and safety of gefitinib, erlotinib, and afatinib in the first-line treatment of advanced non-small cell …
[HTML][HTML] 新辅助化疗, 靶向治疗联合手术治疗临床Ⅲ 期EGFR 阳性肺腺癌
赵晨， 张辉， 刘冬， 张淼， 武文斌… - 中华胸部外科电子 …, 2021 - zhxbwkdzzz.cma-cmc.com.cn
… was no significant difference (P>0.05) ; there was significant difference in tumor differentiation
… of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer …
… of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer …
[HTML][HTML] EGFR-TKIs 与化疗比较一线治疗非小细胞肺癌疗效的meta 分析
曹飞飞， 张琳琳， 王双， 钟殿胜， 王燕 - … Journal of Lung Cancer, 2015 - ncbi.nlm.nih.gov
… , EGFR-TKI）应用于非小细胞肺癌（non-small cell lung cancer, NSCLC）一线治疗取得较好的临床
疗效… By comparison, first-line EGFR-TKI treatment was not a suitable choice for unselected …
疗效… By comparison, first-line EGFR-TKI treatment was not a suitable choice for unselected …
[HTML][HTML] EGFR 基因21 外显子L858R 突变肺腺癌患者化疗和靶向治疗疗效的回顾性分析
罗萌， 徐瑜， 胡义德 - 中华肺部疾病杂志(电子版), 2017 - zhfbjbzz.cma-cmc.com.cn
… Retrospective study on the differences of efficacy of chemotherapy and epidermal growth …
factor for gefitinib treatment in patients with non-small cell lung cancer[J]. Clin Cancer Res, …
factor for gefitinib treatment in patients with non-small cell lung cancer[J]. Clin Cancer Res, …
[HTML][HTML] TP53 突變對具有EGFR 突變的非小細胞肺癌患者帶來的影響
YX Li - 2020 - ir.lib.ncu.edu.tw
… Lung cancer is mainly divided into small cell lung cancer and … inhibitors (TKIs) like gefitinib,
afatinib, and osimertinib are known to … curve to analyze and discuss the difference in survival …
afatinib, and osimertinib are known to … curve to analyze and discuss the difference in survival …
[HTML][HTML] 非小细胞肺癌EGFR 基因突变治疗方案及医保政策回顾
高婧， 王睿， 申越， 尹楠， 王文杰… - World Journal of Cancer …, 2022 - hanspub.org
… mutations in patients with non-small cell lung cancer (NSCLC)… EGFR基因突变患者发现,Gefitinib组
,Erlotinib组和Icotinib组之间… 年4月,中国允许Afatinib被用于NSCLC患者的治疗.LUX-Lung7…
,Erlotinib组和Icotinib组之间… 年4月,中国允许Afatinib被用于NSCLC患者的治疗.LUX-Lung7…
[PDF][PDF] 非小细胞肺癌患者EGFR‑TKI 相关间质性肺疾病发生情况的meta 分析
李姗姗， 徐晓涵， 吴紫阳， 翟所迪， 温剑， 程吟楚 - 药物不良反应杂志, 2022 - cadrj.com
… disease in patients with non‑small cell lung cancer treated with … was no significant difference
in ILD occurrence between the trial group and the control group for afatinib and erlotinib (all …
in ILD occurrence between the trial group and the control group for afatinib and erlotinib (all …
[HTML][HTML] 抗血管生成药物联合EGFR-TKI 治疗EGFR 突变晚期非小细胞肺癌的研究进展
李博文， 薛剑超， 王亚东， 黄志诚， 梁乃新… - … Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… 晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的标准治疗… -mutated advanced
non-small cell lung cancer (NSCLC). … However, compared to EGFR-TKI monotherapy, the benefits …
non-small cell lung cancer (NSCLC). … However, compared to EGFR-TKI monotherapy, the benefits …
[PDF][PDF] 沙利度胺联合吉非替尼靶向治疗非小细胞肺癌的临床效果观察
王宏， 夏永寿， 加静， 张燕… - Progress in Modern …, 2018 - biomed.cnjournals.com
… with gefitinib in the treatment of non-small cell lung cancer. … Comparison of gefitinib,
erlotinib and afatinib in non-small … line treatment for non small cell lung cancer (NSCLC)[J]. …
erlotinib and afatinib in non-small … line treatment for non small cell lung cancer (NSCLC)[J]. …
[HTML][HTML] 化疗间插联合EGFR-TKIs 对比单独化疗一线治疗晚期非小细胞肺癌的meta 分析
洪超煜， 梅同华， 王进 - Chinese Journal of Lung Cancer, 2016 - ncbi.nlm.nih.gov
… 肺癌(non-small cell lung cancer, NSCLC)的有效性及安全性。 … to gefitinib in the treatment of
advanced non-small cell lung … A randomized, controlled, multicenter clinical trial comparing …
advanced non-small cell lung … A randomized, controlled, multicenter clinical trial comparing …